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Background: Loss-of-function point mutations in the cathepsin C gene are the underlying genetic event in
patients with Papillon-Lefèvre syndrome (PLS). PLS neutrophils lack serine protease activity essential for cathelicidin
LL-37 generation from hCAP18 precursor.
Aim: We hypothesized that a local deficiency of LL-37 in the infected periodontium is mainly responsible for one of
the clinical hallmark of PLS: severe periodontitis already in early childhood.
Methods: To confirm this effect, we compared the level of neutrophil-derived enzymes and antimicrobial peptides
in gingival crevicular fluid (GCF) and saliva from PLS, aggressive and chronic periodontitis patients.
Results: Although neutrophil numbers in GCF were present at the same level in all periodontitis groups, LL-37 was
totally absent in GCF from PLS patients despite the large amounts of its precursor, hCAP18. The absence of LL-37
in PLS patients coincided with the deficiency of both cathepsin C and protease 3 activities. The presence of other
neutrophilic anti-microbial peptides in GCF from PLS patients, such as alpha-defensins, were comparable to
that found in chronic periodontitis. In PLS microbial analysis revealed a high prevalence of Aggregatibacter
actinomycetemcomitans infection. Most strains were susceptible to killing by LL-37.
Conclusions: Collectively, these findings imply that the lack of protease 3 activation by dysfunctional cathepsin
C in PLS patients leads to the deficit of antimicrobial and immunomodulatory functions of LL-37 in the gingiva,
allowing for infection with A. actinomycetemcomitans and the development of severe periodontal disease.
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Papillon-Lefèvre syndrome (PLS), a rare autosomal reces-
sive disease, with an incidence of 1–4 cases/million people
is characterized by palmar and plantar hyperkeratosis and
severe periodontitis affecting primary and permanent
teeth leading to early loss of primary and permanent teeth
[1,2]. This periodontitis is classified as a periodontitis as a
manifestation of systemic diseases associated with genetic
disorders [3]. PLS is caused by lost-of-function mutations
in the cathepsin C (CTSC) gene [4,5]. To date, more than
50 different mutations have been identified and since* Correspondence: sigrun.eick@zmk.unibe.ch
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unless otherwise stated.cathepsin C activity is essential for activation of neutrophil
elastase, cathepsin G, protease 3 and neutrophil serine
protease 4 [6,7], PLS neutrophils show no or severely
reduced activity of these four enzymes [8]. Nevertheless,
despite this deficiency, only rarely recurrent invasive bacter-
ial infections, e.g. a pyogenic liver abscess are reported [1].
Periodontitis in general is characterised by inflammation
of the supporting tissues surrounding the teeth and is one
of the most prevalent inflammatory diseases in humans.
The prevalence of severe periodontitis increases with age,
ranging from 1% in young individuals to about 30% in the
older population [9]. Disease is initiated by colonization of
certain bacterial species which may change via immuno-
modulation a symbiotic microbiota into a dysbiotic one,
e.g. recently Porphyromonas gingivalis was postulated to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a form starting normally in adolescence, Aggregatibacter
actinomycetemcomitans is highly prevalent, its virulence
was mainly equated to the production of a leukotoxin [11].
Polymorphonuclear neutrophils (PMNs) play a major
role in immune defence against bacteria. Three serine
proteases, proteinase 3 (PR3), neutrophil elastase (NE)
and cathepsin G (CTSG), which are components of the
neutrophil azurophilic granules, participate in the intra-
cellular killing of phagocytosed pathogens [6]. Further,
neutrophils are the most abundant source of the anti-
microbial peptides α-defensins 1–4 (human neutrophil
peptides 1–4, HNPs 1–4) and hCAP18/LL-37. HNP1-4
are synthesized as prepro forms and stored in a fully
processed, biologically active form in primary granules
in PMNs [12].
The sole human cathelicidin (hCAP18/LL-37) is encoded
by the CAMP gene, and encompasses two distinct domains.
The N-terminal, “cathelin-like” domain is structurally con-
served amongst vertebrates, which is in stark contrast to
the highly diverse antimicrobial peptide constituting the
C-terminal domain [13]. The human cathelicidin is highly
expressed in the myeloid-linage of bone marrow cells, and
also in many types of epithelial cells [14]. In neutrophils
hCAP18/LL-37 is stored in specific (secondary) granules
as a biologically inactive precursor. During phagocytosis,
or in otherwise stimulated neutrophils, bactericidal pep-
tide LL-37 is released from hCAP18/LL-37 by limited
proteolysis, which is exerted by PR 3 [15].
There has been reported a consistent association of
severe periodontitis with a number of syndromic diseases,
especially with those involving neutrophil disorders such
as deficient numbers of polymorphonuclear leukocytes
or aberrant neutrophil function [2]. E.g., patients with
Kostmann syndrome have a lack of bactericidal peptide
LL-37 [16], other severe congenital neutropenia types
affect neutrophil elastase [17]. Recently it was shown
that exocytosed material of peripheral blood PMNs of
the PLS patients contained abundant hCAP-18 but low
levels of LL-37 [18].
Here, we postulate that lack of functional cathepsin C in
PLS patients is associated with the absence of functional
LL-37 in the gingival region. We further hypothesize
that the lack of LL-37 in periodontal tissue is a pivotal
factor in the development of severe periodontitis in
PLS patients. Towards this aim, levels of hCAP18, LL-
37 and neutrophil defensins in gingival crevicular
fluid, saliva and peripheral neutrophils of PLS patients
were quantified and correlated to LL-37 susceptibility of
clinical strains of the causative organism, Aggregatibacter
actinomycetemcomitans. Cumulatively, our results strongly
suggest that antimicrobial and immunomodulatory
functions of LL-37 are essential for homeostasis of the
periodontium.Material and methods
Subjects
A total of 11 PLS patients (two females) were examined at
the Department of Periodontology, Center for Dental, Oral,
and Maxillofacial Medicine, Goethe-University Frankfurt/
Main. Fasting venous blood and saliva samples were
collected from all 11 patients but gingival crevicular fluid
only from eight individuals (two were edentulous, one sam-
ple failed collection) (Additional file 1: Table S1) [19-24].
Blood was collected from the antecubital fossa (lithium
heparin tube, Monovette, Sarstedt AG, Nümbrecht,
Germany) from PLS patients and PMNs were isolated
using dextran sedimentation followed by hypotonic
lysis of erythrocytes. Then cells were resuspended with
Hanks balanced salt solution (HBSS) to a density of
3.3*106/mL. PMNs from three healthy subjects prepared
in the same way were used as positive controls.
A cohort of patients attending the Center for Dental,
Oral and Maxillary Medicine at the University Hospital of
Jena was recruited for this study. The subjects included
seven patients with aggressive periodontitis (AP; mean age
30.9 years) and 12 with chronic periodontitis (CP; mean
age 56.3 years). The patients were diagnosed according
to recommendation by the American Academy of Peri-
odontology [3]. Severe periodontitis was diagnosed as
an attachment loss of ≥5 mm at a minimum of five sites,
in different quadrants, after receiving initial therapy. Nine
periodontally healthy subjects were included as a control
group (con; mean age 32.2 years). Subjects were free of
systemic diseases, and had at least 20 teeth in occlusion.
Less than 35% of the patients were active smokers.
Individuals who had received systematic periodontal
treatment in the preceding year, those who had taken
antibiotics within the previous 3 months, or those who
were pregnant or nursing were excluded from this
study. Clinical examinations included plaque index as a
measure for oral hygiene, bleeding on probing (BoP) as
a common used index associated with inflammation,
probing depths and attachment loss at six sites per tooth.
Furthermore, the plaque index had to be less than 0.35 to
be selected for the study.
The study protocol was approved by the Ethics Com-
mittees of the Universities of Jena (#2030-05/07) and
Frankfurt (#31/05), Germany. All participants gave their
informed consent.
Sampling of saliva and crevicular fluid
From all subjects included in the study, saliva and gingival
crevicular fluid (GCF) samples (only dentate individuals)
were collected in the morning, 2–3 h after breakfast.
Whole saliva samples were collected using a sterile glass
funnel into weighed 10 mL sterile polypropylene con-
tainers for 10 minutes. No oral stimulus was permitted for
120 minutes prior to collection to exclude any influence
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the saliva over the period and pooled the saliva in the
bottom of the mouth and drained to a collection tube
when necessary.
Crevicular washes were obtained using a previously
described method [25]. The sites to be sampled were
isolated with cotton rolls and gently air-dried. A tip was
carefully inserted into the crevice at a level of approxi-
mately 1 mm below the gingival margin. In each case,
seven sequential washes with 10 μL phosphate-buffered
saline were performed using a micropipette. The GCF
was obtained as a pooled sample from the deepest site
in each quadrant, and transferred into an Eppendorf
tube. After this, samples were immediately frozen and
kept at −20°C until analyzed.
Microbiota
DNA was extracted from 5 μL of GCF washing using
the Genomic Mini Kit (A&A Biotechnology, Gdynia,
Poland) according to the manufacturer’s recommendations.
Real-time PCR for determining the counts of A. actinomy-
cetemcomitans, P. gingivalis, P. intermedia, T. forsythia and
T. denticola was carried out as described recently [26].
ELISAs
MPO and α-defensin were detected in GCF and saliva
samples using Human MPO and Human HNP1–3 (neu-
trophil defensins) ELISA test kits, respectively, according
to manufacturer’s protocol. Both kits were obtained from
HyCult Biotechnology (Uden, The Netherlands). Samples
were diluted 10-100-fold (saliva), and 10,000-fold (GCF),
in PBS and plasma dilution buffer, respectively, for MPO
and defensins determination.
Enzyme activities
Enzyme activities of CTSC and the neutrophil serine pro-
teases NE and PR3 were determined in GCF, saliva and
neutrophil lysates from control subjects and PLS patients.
Cell lysates were obtained by mixing the neutrophil
suspension at a 1:1 ratio with 0.1% hexadecyltrimethyl
ammonium bromide (CTAB) followed by incubation at
37°C for 15 min.
The CTSC activity was assayed using H-glycyl-L-ar-
ginine-7-amido-4-methylcoumarin (H-Gly-Arg-AMC)
(Bachem, Weil, Germany) as a substrate at 500 μM
final concentration of 25 mM 2-(N-morpholino)etha-
nesulfonic acid (MES, Sigma, Munich, Germany),
50 mM NaCl, and 5 mM dithiothreitol (DTT) at pH 6.0.
The enzymatic substrate turnover was monitored as the
increase of fluorescence (excitation and emission wave-
lengths at 380 nm and 460 nm, respectively) for 60 min
using a Spectramax GEMINI XS (Molecular Devices
Corp., Sunnyvale, CA, USA).The NE activity was determined by measuring the rate of
release of p-nitroanilide (pNa) from N-methoxysuccinyl-
Ala-Ala-Pro-Val-p-nitroanilide (MeSuc-AAPV-pNA) used
as substrate (Sigma, Munich, Germany). The assay was
performed in total volume of 150 μL with 0.75 mM final
substrate concentration in 50 mM Tris–HCl, pH 7.5. The
rate of pNA released was recorded at 405 nm using a
Spectromax 250 (Molecular Devices Corp., Sunnyvale,
USA) for 30 min.
PR3 activity was determined using Abz-GVADnVADYQ-
Y(N02)-D (nV, norvaline) as a substrate at final concentra-
tion of 50 μM in 0.1 M Tris–HCl, 5 mM EDTA, 0.15 M
NaCl, 0.05% Tween-20, 5% dimethylforamide, pH 7.5.
Substrate hydrolysis was measured as an increase of
fluorescence at λex = 320 nm and λem = 420 nm for 3 h
at 37°C using a Spectramax GEMINI XS.
The activity of CTSC, NE and PR3 in GCF and saliva
was calculated as a percentage of activities of individual
proteases in lysates of healthy control neutrophils set
as 100%.
Western blot of LL-37
Semiquantitative Western blot analysis of LL-37 was
performed as described recently [27]. GCF and saliva
samples were diluted 4 times with sample buffer
(0.125 mM Tris–HCl, 20% glycerol, 4% SDS), and resolved
by SDS-PAGE (16% peptide gel (49.5%T/6%C)) using the
Tris-Tricine discontinuous buffer system [28]. LL-37
was synthesized on an Applied Biosystems model 433A
synthesizer, and purified by preparative reversed-phase
high-performance liquid chromatography (HPLC) [29]. It
was used at a concentration of 20 ng/mL (6 ng/well =
4 μg/mL) as a standard. Electrophoresed gels were
electroblotted (Trans-Blot Semi-Dry; Bio-Rad) onto poly-
vinylidene difluoride (PVDF) membranes (Amersham-
Pharmacia Co., Uppsala, Sweden). Nonspecific binding
sites on the membranes were blocked overnight in 5%
skimmed milk (Difco) and immunoblotted. The blots were
probed with monoclonal mouse antibodies against LL-37
(clone 1.1C12, 42) and goat anti-mouse IgG horse-raddish
peroxidase conjugated antibodies (Sigma). Immunoreac-
tive peptides were detected with ECL Plus (Amersham-
Pharmacia Co.) according to manufacturer’s protocol,
before membranes were exposed to X-ray films (Kodak,
Rochester; NY; USA).
Determination of antimicrobial activity against
Aggregatibacter actinomycetemcomitans
Suspensions of several strains of A. actinomycetemcomitans
(ATCC 33844 and six clinical isolates) were preincubated
with different concentrations of LL-37 for 1 h at 37°C.
Strains incubated in the same conditions but without the
peptide constituted the control of survival (100% survival).
After incubation bacteria were suspended and plated on
A)
B)
Figure 1 Papillon Lefèvre syndrome patient. Clinical view of a
Papillon-Lefèvre syndrome patient at 5 years age (#3, Table 1) with
typical symptoms: severe periodontitis with a periodontal abscess at
the upper central incisor 51 (A) and plantar hyperkeratosis (B).
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4 days of cultivation in anaerobic atmosphere.
Data analysis
All data were entered into the SPSS 21.0 (SPSS Inc,
Chicago, IL, USA) program, and were analyzed using
the Kruskal-Wallis test. Mann–Whitney U-test was
used for comparisons with PLS and periodontal healthy
subjects each. In GCF, correlations using Spearman test
were determined in PLS group and the subjects without
known genetic disorders. The level of significance was
set to p < 0.05.
Results
PLS patients
The characteristics, including year of birth, ethnicity, gen-
der, phenotype, the presence of A. actinomycetemcomitans
in subgingival plaque before treatment and mutation
in the CTSC gene (nucleotide, exon, affected amino
acid residue) of the 11 PLS patients are summarized in
Additional file 1: Table S1). A. actinomycetemcomitans
was detected in all 9 microbiologically characterized
samples before periodontal treatment. Ten out of 11
patients exhibited typical skin lesions. Clinical view of
one of the patients is presented in Figure 1. In one
patient onset of periodontitis was late (at the age of 22)
but, nevertheless, led to edentulism (Additional file 1:
Table S1). CTSC, NE and PR3 activity was measured in
peripheral blood neutrophils of PLS patients. The CTSC
activity was absent in neutrophils from nine patients while
in two patients it was detected at the low level (up to 10%
of the average activity of three matched healthy controls).
In none of neutrophil lysates from PLS patients the PR3
activity was measurable. Low NE activity (at 2.6% of
controls) was detected only in one patient with the
highest CTSC activity (at 10% of control neutrophils).
For the purpose of this study GCF sampled from eight
of the nine dentate patients has been analysed again for
bacteria present there. The results were compared to
simultaneously performed analysis of samples derived
from patients with chronic and aggressive periodontitis, as
well as healthy controls. Significantly, despite intensive
treatment A. actinomycetemcomitans was still detected in
GCF from four out of the eight PLS patients at the similar
prevalence as in GCF from non-treated aggressive
periodontitis. On the other hand, the prevalence of P.
gingivalis and T. denticola was much higher in chronic
periodontitis than in PLS patients and the aggressive
form of the disease (Table 1). No periodontal pathogens
were found in healthy controls.
MPO as an equivalent for neutrophil numbers
Myeloperoxidase (MPO) occurs in high amounts exclusively
in neutrophils and its concentration in pathophysiologicalfluids reflects neutrophil level [27]. Therefore we deter-
mined MPO concentration to illustrate relative abundance
of neutrophils in our samples. In saliva of PLS patients the
median concentration of MPO was determined at 864 pg/
ml (range 116 – 2050 pg/ml), thus higher, although with-
out statistical significance, than in other subject groups
(CP: 747 pg/ml, range 522–790 pg/ml; AP: 591 pg/ml,
range 472–621 pg/ml, controls: 533 pg/ml, range 237–
836 pg/ml) (Figure 2A). However, after exclusion of the
edentulous patients in the PLS group (median 909 pg/ml,
range 496–2050 pg/ml), significantly higher concentration
of MPO (p < 0.05) was found in the PLS saliva than in the
saliva from other groups.
In GCF, results were similar, the highest levels of MPO
were also measured in samples derived from PLS patients
(median 7.50 ng/μl, range 1.95-13.90 ng/μl), followed
by chronic periodontitis patients, aggressive periodon-
titis, and periodontally healthy controls, respectively
(Figure 2B). Nevertheless, no significant difference was
observed between any groups of samples.
α-Defensins
The levels of α-defensins in saliva of PLS patients (median
0.33 μg/ml, range 0.00-6.58 μg/ml) were not strikingly
Table 1 Prevalence of the periodontopathogens Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis,
Tannerella forsythia, Treponema denticola and Prevotella intermedia in gingival crevicular fluid obtained from PLS
patients (at the time of the study), periodontitis patients as well as healthy controls





subjects (n = 9)
A. actinomycetemcomitans 4 (50%) 4 (57%) 4 (33%) 0 (0%)
P. gingivalis 0 (0%) 4 (57%) 10 (83%) 0 (0%)
T. denticola 1 (13%) 3 (43%) 7 (58%) 0 (0%)
T. forsythia 3 (38%) 4 (57%) 11 (92%) 0 (0%)
P. intermedia 1 (13%) 2 (29%) 6 (50%) 0 (0%)
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(AP: median 0.25 μg/ml, range 0.00-0.5 μg/ml, and
controls: median 0.45 μg/ml, range 0.00-6.6 μg/ml). In
contrast, chronic periodontitis patients possessed rela-
tively high concentration of HNP1-3 in saliva (median
3.62 μg/ml, range 0.12-19.76 μg/ml) (Figure 2C).
In contrast to saliva, HNP1-3 were detected in GCF
from PLS patients (median: 28.98 μg/μl, range: 0.14-
103.94 μg/μl) in significantly higher concentration in
comparison with periodontally healthy controls (median:
1.20 μg/μl, range: 0–29.19 μg/μl). Only moderate amounts
of HNP1-3 were detected in samples from aggressive
periodontitis (median: 15.29 μg/μl, range: 0.36-49.61 μg/μl).
In chronic periodontitis patients however, the levels of
HNP1-3 were high (median: 50.63 μg/μl, range: 0.40-
116.17 μg/μl) (Figure 2D). Significantly, both in PLSFigure 2 Levels of myeloperoxidase and α-defensins in saliva and gin
and α-defensins (HNP1-3) (C and D) in saliva (A and C) and gingival crevic
aggressive periodontitis patients (AP), chronic periodontitis patients (CP) an
75th percentiles.patients and combined periodontitis patients (AP + CP)
the levels of MPO correlated well with amount of
detected HNP1-3 (PLS: r = 0.742, p = 0.035; CP + AP:
r = 0.533, p = 0.004).
hCAP18 and cathelicidin LL-37
Except for edentulous PLS patients, the unprocessed
cathelicidin hCAP18 was always detected in saliva.
hCAP18 was present in highest levels in PLS, followed
by chronic periodontitis patients and in low abundance
in AP patients’ and healthy control individuals’ saliva
(Figure 3A). This probably reflects the relatively high level
of neutrophils in saliva from PLS and chronic periodon-
titis groups (Figure 1). The lack of hCAP18 in saliva of
edentulous PLS patients correlates with the near absence
of neutrophils as indicated by very low amount of MPO ingival crevicular fluid. Levels of myeloperoxidase (MPO) (A and B)
ular fluid (B and D) obtained from Papillon-Lefèvre patients (PLS),
d healthy controls (con). The results present median, and 25th and
Figure 3 Levels of unprocessed cathelicidin hCAP18 and mature LL-37 in saliva and gingival crevicular fluid. Levels of unprocessed cathelicidin
hCAP18 and mature LL-37 in saliva (A) and gingival crevicular fluid (C) obtained from Papillon-Lefèvre patients (PLS), aggressive periodontitis patients
(AP), chronic periodontitis patients (CP) and healthy controls (con) determined by western blot analysis. The results present median, and 25th and 75th
percentiles. Panel B shows Western blot patterns of LL-37 immunoreactive proteins/peptides in GCF samples collected from PLS patients (#1 - #11) as well
as representative samples of chronic periodontitis (CP) and aggressive periodontitis (AP) as well as from healthy controls (con). Arrows point to bands
immunoreactive against anti-LL-37 antibody, representing intact hCAP18/LL-37, 11 kDa fragment of hCAP18/LL-37, and the LL-37 peptide.
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the gingival crevice around teeth is a major port of entry
for neutrophils into the oral cavity. But using Western
blot analysis with mAb anti-LL-37 we failed to detect
mature LL-37 peptide in any saliva samples regardless
of disease status.
High levels of hCAP18, comparable to that of CP, AP
and healthy controls, were detected in five (out of eight)
analysed samples of GCF from the PLS patients. In three
remaining samples barely visible amounts of hCAP18
were found (Figure 3B). In general, the estimated amountof hCAP18 in PLS patients was comparable to that of
healthy subjects but lower than in GCF from AP and CP
patients (Figure 3C).
Although the LL-37 peptide was found in all GCF
samples from periodontally healthy controls, the level
of the peptide in CP patients was significantly higher
(Figure 3C). In the later group the amount of hCAP18
correlated with mature LL-37 (r = 0.523, p < 0.001) and the
load of P. gingivalis (r = 0.644, p < 0.001). In AP patients
LL-37 was detected at concentrations higher than in
controls but the difference was not significant. In strike
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in any of GCF samples of PLS patients despite in part the
abundant presence of the precursor protein (Figure 3B).
Interestingly in this group the level of hCAP18 showed
a correlation to the load of A. actinomycetemcomitans
(r = 0.793, p = 0.019). Of note, the lack of LL-37 in these
samples was not due to proteolytic degradation of the
peptide since the externally added peptide was intact in
GCF samples even after 24 h incubation (data not shown).
Activities of cathepsin C, neutrophil elastase and
proteinase 3
We failed to find any CTSC activity in nine out of 11
PLS saliva samples. In all other samples CTSC activity
was detected but at highly variable levels. In patients
with CP and AP the CTSC activity was slightly higher,
but not significantly, compared to periodontally healthy
controls (Figure 4A). The lack of the CTSC activity
coincided in PLS patients with very low levels of the NE
activity comparable to that in saliva from periodontallyFigure 4 Activities of cathepsin C, neutrophil elastase and proteinase
(CTSC) (A and D), neutrophil elastase (NE) (B and D) and PR3 (C and E) in
Papillon-Lefèvre patients (PLS), aggressive periodontitis patients (AP), chron
present median, and 25th and 75th percentiles.healthy subjects where the enzyme activity was detected
in two out of nine analysed samples. In contrast, the NE
activity was high in chronic (CP versus PLS and controls:
p < 0.001) and aggressive periodontitis patients (AP versus
PLS and controls: p = 0.005 and p = 0.006, respectively)
(Figure 4B).
The PR3 activity was detected in six out of the 11 PLS
saliva samples (among them in two with the measurable
CTSC activity) but at much lower level than in other
groups. With exception of one periodontally healthy
subject the PR3 activity was present in all other samples
(Figure 4C). Significantly, no PR3 activities were detected
in saliva of the edentulous PLS patients in keeping with
the low level of MPO. This further supports the conclu-
sion that the junction or pocket epithelium around teeth
is the most important gate for neutrophils migration into
the otherwise healthy oral cavity.
In GCF, the activity of CTSC varied considerably
between the groups (p < 0.001). In five samples of PLS
patients the CTSC activity was absent while in three other3 in saliva and gingival crevicular fluid. Activities of cathepsin C
saliva (left panels) gingival crevicular fluid (right panels) obtained from
ic periodontitis patients (CP) and healthy controls (con). The results
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correlated with the lack of the NE (Figure 4E) and PR3
activities (Figure 4F). In general, the CTSC activity in GCF
from PLS was far below that in periodontally healthy
subjects (p = 0.002). Conversely, in CP and AP groups the
CTSC activity was significantly higher than in healthy
controls (AP 103-fold: p = 0.001; CP 66-fold: p = 0.004)
(Figure 4D).
Activity of LL-37 against Aggregatibacter
actinomycetemcomitans strains
With the exception for one clinical isolate of serotype c,
which was resistant, all other tested strains were moder-
ately susceptible to bactericidal activity of LL-37 (Table 2).
The resistance does not seem to correlate with the strain
serotype since three other strains of the same serotype
were sensitive.
Discussion
PLS is caused by different mutations in the CTSC gene
resulting in typical and atypical pathological outcomes,
including those with isolated keratosis and periodontitis
[5,24]. Here 11 patients among them nine with typical
signs of PLS, including palmoplantar hyperkeratosis and
severe early onset periodontitis already in the deciduous
dentition in some patients, have been analysed. One
patient (#2) had periodontitis of the deciduous dentition,
but only suffered from mild skin symptoms. Another
PLS patient (#7) suffered from typical skin symptoms,
however, exhibited late onset of periodontitis (Additional
file 1: Table S1). In all cases we have shown that muta-
tions affected the CTSC activity, never exceeded 10% of
the average activity of systemically healthy subjects.
Furthermore, we confirmed the observation by Cagli
et al. [30] that the expression of dysfunctional CTSC
correlated with severely decreased activity of PR3, NE
and cathepsin G in neutrophils.Table 2 Minimal bactericidal concentrations (MBC) of
LL-37 against Aggregatibacter actinomycetemcomitans
strains




ATCC 33384 Laboratory strain 50 70
J1 Clinical isolate 20 70
J2 Clinical isolate 10 50
J3 Clinical isolate 20 50
J7 Clinical isolate 10 50
J11 Clinical isolate 70 >150
J76 Clinical isolate 20 70
MBC50 and MBC90 indicate the minimal bactericidal concentration (MBC)
values at which 50% and 90% of bacterial cells were killed, respectively.In oral fluids such as saliva and GCF from PLS subjects,
the CTSC activity was most absent or detected at very low
levels in comparison to the activity in other periodontitis
patients and even the periodontally healthy subjects.
Deficiency of the CTSC activity in tested fluids was
associated with the absence or severe reduction of activity
of neutrophil serine proteases, such as NE and PR3. Thus,
the inflammatory response to pathogenic bacteria must be
disturbed in PLS patients since neutrophil serine proteases
activate gingival fibroblasts to produce inflammatory cyto-
kines [31] and are components of neutrophil extracellular
traps which trap and kill pathogens [32]. Further, reactive
oxygen species generation and MPO activity is not suffi-
cient to kill microbes and proteases are primarily respon-
sible for the destruction of phagocytosed bacteria [33]. This
antibacterial activity is exerted in different manners. For
example, NE cleaves outer membrane proteins in Gram
negative bacteria [34]. In keeping, it was shown that neutro-
phils from peripheral blood of PLS patients were incapable
of neutralizing leukotoxin produced by A. actinomycetem-
comitans in the process dependent on serine proteases [18].
In stark contrast to saliva samples from PLS patients
half of which contain the low but detectable PR3 activity,
no trace of the PR3 activity was detected in GCF. Interest-
ingly, in four cases the PR3 activity was found in saliva
totally deficient of the CTSC activity. This suggests a pos-
sible activation of PR3 by other proteases present in saliva.
This is in keeping with results of a study using a leukae-
mia cell line which indicated that cathepsin C is not the
sole enzyme involved in post-translational processing of
PR3 [35]. The results implicated PR3 as a promising
screening parameter for detection of periodontitis because
the PR3 activity was significantly higher in every peri-
odontitis patient without known genetic disorder than
in any periodontally healthy control. This conclusion is
supported by the recent finding that the PR3-like activity
was increased in saliva of periodontitis patients and
correlated with severity of the disease [36]. The missing
activity in GCF of PLS patients can be an additional hint
for checking genetic disorders in selected periodontitis
patients. PR3 seems to be an important player in the
process of inflammation since it activates oral epithelial
cells to produce interleukin-8 and monocyte chemo-
attractant protein as well as to express intracellular
adhesion molecule (ICAM)-1 [37]. This might be in
accordance to findings that IL-8 levels were lower in GCF
of PLS patients in comparison with controls [38]. In
addition, chemotaxis of PMNs to IL-8 is diminished in
PLS [39]. However in GCF of PLS patients, neutrophils
are present in abundant numbers and this is associated
with high levels of α-defensins, other important neutrophil
derived antimicrobial peptides. But the used method does
not allow distinguishing between the HNP1 precursor
and functional HNPs. Considering the postulated role of
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HNP-1 [40], the lack of their activity in PLS neutrophils
may also cause the deficiency of active HNP1 in periodon-
tal lesions of PSL patients.
Our results indicate that the lack of active neutrophil
serine proteases and mature LL-37 is associated with
severity of periodontal disease in PLS patients. Recently
blood of PLS patients was analysed for LL-37 also using
the WB method [18]. In contrast to our finding of the
total absence of the peptide in GCF samples, a low
amount of mature LL-37 and intermediate-size hCAP18-
derived fragments were detected in this study. We found
intermediate hCAP18 fragments in chronic periodontitis
associated with a high prevalence of P. gingivalis, T.
forsythia and T. denticola [27], but never in PLS patients.
This discrepancy may arise from different sources of
analysed material: isolated neutrophils activated in vitro to
degranulate versus clinical samples in which neutrophils
were in vivo exposed to bacteria.
All patients were initially colonized by A. actinomyce-
temcomitans, after receiving an extensive periodontal
treatment still four of eight were tested positively for
that species, however at low counts. This corroborates with
a high prevalence of A. actinomycetemcomitans in PLS
patients found in other studies [20,41]. Recently by using
a 16S rRNA-based microarray A. actinomycetemcomitans
was found among the species in medium to high levels in
13 untreated PLS patients [42]. Our data strongly suggests
that the lack LL-37 is a condition selectively supporting
growth of A. actinomycetemcomitans, the bacterium dir-
ectly linked to development and progression of aggressive
periodontitis. The importance of A. actinomycetemcomi-
tans in PLS patients is underlined by findings of high
IgG titers against that species [41,43] and the fact that a
successful treatment of localized prepubertal periodontitis
in PLS correlates with eradication of A. actinomycetemco-
mitans [20,21].
Interestingly, only in PLS patients the level of unpro-
cessed hCAP18 was correlated with the load of A. actino-
mycetemcomitans. No such correlation between hCAP18
and any periodontal pathogen was found in other groups
clearly due to hCAP18 processing and LL-37 release.
In these patients LL-37 in conjunction with α- and β-
defensins may prevent robust proliferation of A. acti-
nomycetemcomitans generating conditions favouring
the growth of other periodontal pathogens, including
P. gingivalis, T. forsythia and P. intermedia. Indeed, in
periodontitis patients without known genetic disorders
the load of P. gingivalis and the other proteolytic period-
ontopathogens is correlated with activity of CTSC, NE
and PR3 and the released α-defensins and mature LL-37.
Data regarding the susceptibility of A. actinomycetemco-
mitans to the various antibacterial peptides are rare,
strains were totally insensitive to HNP1-3 [44,45] andshow a good to moderate sensitivity to LL-37 [46,47]
which was confirmed by our clinical isolates.
Additionally to the missing direct antimicrobial activity
a disturbance of other functions modulated by LL-37
may be suggested in PLS patients. These include, direct
chemotaxis of immune cells, induction of chemokines,
regulation of chemokine receptor expression, inhibition
of the release of pro-inflammatory mediators, suppression
of neutrophil apoptosis, modification of dendritic cells
differentiation and protection against inflammatory shock
(reviewed in [48]). E.g., LL-37 neutralizes the lipopolysac-
charide activity of certain periodontopathogens among
them A. actinomycetemcomitans in human oral fibroblasts
[49]. Although stimulating in low concentrations proli-
feration of peripheral blood monocytes LL-37 inhibits
in vitro generation of osteoclasts from these cells [50].
These numerous immunomodulatory activities of LL-37
are apparently essential for maintaining homeostasis in
periodontal tissues by providing protective anti-microbial
responses without the excessive harmful inflammation.
Conclusions
In summary, the lack of functional cathepsin C impairs
activation of neutrophil serine proteases in neutrophils
responding to bacterial challenge in periodontium of PLS.
patients. One consequence is the loss of antimicrobial and
immunomodulatory functions of LL-37 in the gingiva.
This supports infection with A. actinomycetemcomitans
and the development of severe periodontal disease.
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